A detailed history of Voya Investment Management LLC transactions in Edgewise Therapeutics, Inc. stock. As of the latest transaction made, Voya Investment Management LLC holds 299,369 shares of EWTX stock, worth $9.21 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
299,369
Previous 24,321 1130.91%
Holding current value
$9.21 Million
Previous $438,000 1724.2%
% of portfolio
0.01%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$15.88 - $29.5 $4.37 Million - $8.11 Million
275,048 Added 1130.91%
299,369 $7.99 Million
Q2 2024

Dec 03, 2024

SELL
$15.08 - $21.23 $4.15 Million - $5.84 Million
-275,048 Reduced 91.88%
24,321 $438,000
Q2 2024

Aug 14, 2024

BUY
$15.08 - $21.23 $90,857 - $127,910
6,025 Added 32.93%
24,321 $438,000
Q1 2024

Dec 06, 2024

SELL
$9.25 - $19.97 $2.6 Million - $5.61 Million
-281,073 Reduced 93.89%
18,296 $333,000
Q1 2024

May 15, 2024

BUY
$9.25 - $19.97 $1,026 - $2,216
111 Added 0.61%
18,296 $333,000
Q3 2023

Nov 14, 2023

BUY
$5.73 - $7.69 $4,171 - $5,598
728 Added 4.17%
18,185 $104,000
Q2 2023

Aug 14, 2023

BUY
$5.71 - $10.29 $21,977 - $39,606
3,849 Added 28.28%
17,457 $135,000
Q4 2022

Feb 14, 2023

BUY
$7.58 - $11.08 $13,090 - $19,135
1,727 Added 14.54%
13,608 $121,000
Q3 2022

Mar 03, 2023

SELL
$8.08 - $13.58 $13,954 - $23,452
-1,727 Reduced 12.69%
11,881 $116,000
Q2 2022

Aug 15, 2022

SELL
$5.67 - $9.87 $16,550 - $28,810
-2,919 Reduced 19.72%
11,881 $95,000
Q1 2022

May 16, 2022

BUY
$9.1 - $18.97 $11,038 - $23,010
1,213 Added 8.93%
14,800 $144,000
Q4 2021

Feb 14, 2022

BUY
$14.41 - $22.41 $195,788 - $304,484
13,587 New
13,587 $208,000

Others Institutions Holding EWTX

About Edgewise Therapeutics, Inc.


  • Ticker EWTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 63,171,700
  • Market Cap $1.94B
  • Description
  • Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has c...
More about EWTX
Track This Portfolio

Track Voya Investment Management LLC Portfolio

Follow Voya Investment Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Voya Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Voya Investment Management LLC with notifications on news.